Skip to main content
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. — Investor Relations & Filings

Ticker · ARTV US Professional, scientific and technical activities
Filings indexed 140 across all filing types
Latest filing 2026-02-24 Regulatory Filings
Country US United States of America
Listing US ARTV

About Artiva Biotherapeutics, Inc.

https://www.artivabio.com/

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf natural killer (NK) cell-based therapies. The company's mission is to create effective, safe, and accessible cell therapies for patients with autoimmune diseases and cancer. Its lead product candidate, AlloNK® (AB-101), is a non-genetically modified, cryopreserved NK cell therapy. AlloNK® is being evaluated in clinical trials in combination with B-cell targeted monoclonal antibodies for the treatment of autoimmune diseases, including rheumatoid arthritis and Sjögren’s disease, and for various cancers. Artiva aims to overcome the limitations of complex and costly patient-specific cell therapies.

Recent filings

Filing Released Lang Actions
8-K - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer)
Regulatory Filings
2026-02-24 English
4 - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer)
Director's Dealing
2026-02-20 English
8-K - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer)
Regulatory Filings
2026-02-19 English
4 - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer)
Director's Dealing
2026-02-19 English
4 - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer)
Director's Dealing
2026-02-19 English
4 - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer)
Director's Dealing
2026-02-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.